Topography-modified refraction (TMR): partial to total adjustment of treated cylinder amount and axis provided by topography data measured vs using the standard clinical refraction in myopic topography-guided LASIK

Session Details

Session Title: Moderated Poster Session: What News from Cornea?
Session Date/Time: Saturday 22/02/2020 | 14:00-15:00
Paper Time: 14:48
Venue: Poster Area


First Author: A.Kanellopoulos GREECE
Co Author(s):                  

Abstract Details

Purpose:

The purpose of this study is to compare the outcomes of 50% and 100% Topography-Modified Refraction (TMR) to each other and to the standard clinical refraction in patients having myopic topography-guided LASIK for myopia.

Setting:

LaserVision.gr

Methods:

In this contralateral, prospective randomized consecutive case series, 240 eyes (120 patients) have undergone myopic (with corresponding astigmatism) topography-guided LASIK. One eye of each patient (Group-A) was treated with the standard clinical refraction (sphere, cylinder and axis), while the contralateral eye with: either 50% Topography-modified refraction (TMR) (group-B); or 100% Topography-modified refraction (TMR) (group-C); The 3 months peri-operative visual performance and refractive data were compared for all three groups.

Results:

Mean pre-operative refractive error was: −4.5 D of myopia and −1.75 D of astigmatism. In average numbers at 3 months: UDVA: 6.25% of group A, 0% of group B and 0% of group C was ≦ 20/20; 25%, 28.57% and 29.34% was 20/20; 68.75%, 71.42% and 70.66% was >20/20 respectively; 1 line of vision gained: 56.25%, 42.85% and 66.67%; 2 or more lines of vision gained was 12.5%, 28.56% and 33.33% also respectively. In-group A, 50% of eyes had less than 0.25 diopters of residual refractive astigmatism, 71.42% in group B (P<.01) and to 77.76% in group C(P<.01).

Conclusions:

Topography-modified refraction (TMR) used in myopic topography-guided cases, appears superior to clinical refraction used. Complete adherence to the topography cylinder amount and axis appears to offer the best outcomes in this contralateral eye comparison.

Financial Disclosure:

None